Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Moderate Buy” by Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have earned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $8.1667.

A number of analysts have weighed in on JSPR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. Wall Street Zen cut shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. Finally, TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Jasper Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after purchasing an additional 23,453 shares during the period. Acadian Asset Management LLC bought a new position in Jasper Therapeutics in the first quarter worth approximately $46,000. JPMorgan Chase & Co. increased its holdings in Jasper Therapeutics by 1,074.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 65,088 shares of the company’s stock worth $361,000 after purchasing an additional 59,547 shares during the period. XTX Topco Ltd purchased a new position in Jasper Therapeutics during the 2nd quarter worth $152,000. Finally, Marshall Wace LLP bought a new stake in Jasper Therapeutics during the 2nd quarter valued at $281,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Stock Performance

JSPR opened at $0.72 on Monday. The stock has a market cap of $23.83 million, a price-to-earnings ratio of -0.45 and a beta of 3.02. The stock’s 50 day moving average price is $0.62 and its 200-day moving average price is $0.87. Jasper Therapeutics has a one year low of $0.32 and a one year high of $3.05.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. As a group, analysts predict that Jasper Therapeutics will post -1.32 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.